H.R. 4866
Referred to CommitteeNational Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
Latest Action
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
9/22/2020 • Senate
Summary
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)
Passed House • 9/21/2020
Topics & Subjects
CBO Cost Estimates (1)
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (3)
Party Breakdown
Sponsor
Cosponsors (2)
Bill Journey
Originated in the House
Introduced
October 28, 2019
Committee Review
March 11, 2020
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Floor Debate
September 21, 2020
Passed Chamber
September 21, 2020
Other Chamber
President
Enacted into Law
Text Versions (4)
Committee Reports (1)
Related Bills (4)
H.R. 6379
Workforce Emergency Response Act of 2020
H.R. 6800
The Heroes Act
H.R. 14
Commitment to Defeat the Virus and Keep America Healthy Act
H.R. 5568
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2018